한글목차

세계의 강압제 시장은 2030년까지 297억 달러에 도달

2023년에 246억 달러로 평가된 세계의 강압제 시장은 분석 기간 2023년부터 2030년까지 CAGR 2.8%로 성장할 전망이며, 2030년에는 297억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 칼슘 채널 차단제는 CAGR 3.2%로 성장을 지속하고, 분석 기간 종료 시 72억 달러에 달할 것으로 예상됩니다. ACE 억제제 부문의 성장률은 분석 기간 동안 CAGR 3.7%로 추정됩니다.

미국 시장은 67억 달러로 추정, 중국은 CAGR 4.7%로 성장 예측

미국의 강압제 시장은 2023년 67억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 58억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023년부터 2030년까지 CAGR은 4.7%로 전망됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.5%와 2.3%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 1.9%로 성장할 것으로 예측됩니다.

세계의 강압제 시장 동향-주요 동향 및 촉진요인 요약

세계의 강압제 시장은 제약 업계의 주요 부문이며, 세계에서 약 15억 명이 앓고 있는 고혈압의 만연이 큰 원동력이 되고 있습니다. 고혈압은 세계적으로 가장 흔한 만성 질환 중 하나임에도 불구하고 최근 혈압의 메커니즘과 새로운 치료법에 대한 혁신적인 연구가 현저하게 감소하고 있습니다. 특히 저소득국가에서 고혈압 부담이 증가하고 있는 것 외에 부유한 국가에서는 진단부족과 치료부족이 계속되고 있기 때문에 이 감소는 특히 우려됩니다.

고령화, 비만율 증가, 앉기 쉬운 라이프 스타일, 높은 염분 섭취량 등 식생활의 혼란 등이 배경에 있으며, 강압제 수요는 계속 성장하고 있습니다. 이에 대응하기 위해 이 시장에서는 치료요법을 간소화하기 위해 복수의 약제를 단일 투여형으로 배합한 병용요법 등 보다 뛰어난 효능, 부작용의 경감, 환자의 컴플라이언스 향상을 실현 하는 신약 요법의 개척으로 이동하고 있습니다. 또한, 유전체학 및 생명공학의 진보로 치료에 대한 개별화 접근법에 대한 길이 열리고 있어, 개별 환자의 유전자 프로파일에 맞춘 투약이 가능해져 고혈압 관리의 효능이 높아지고 있습니다.

신흥국에서는 중산계급의 확대와 의료보험제도의 충실에 의해 강압 치료에 대한 액세스가 대폭 늘어나고 있습니다. 이러한 확대는 고혈압의 위험에 관한 국민의 의식을 높이고 효과적인 관리 방법을 촉진하는 것을 목적으로 하는 정부나 헬스케어에 대한 대처에 의해 지원되고 있습니다. 또한 스마트폰 앱과 연동한 디지털 혈압 모니터 등 가정 의료 모니터링 기술의 대두는 환자가 자신의 상태를 실시간으로 모니터링할 수 있게 함으로써 보다 나은 환자 참여와 치료에 대한 어드히어런스를 촉진하고 있습니다. 그러나 제약업계는 엄격한 규제환경이나 약가 인하압력 등의 과제에도 직면하고 있으며, 제약회사는 비용대비 효과가 높은 의약품의 제조 및 유통방법에 대한 혁신을 강요받고 있습니다.

조사 대상 기업 예(총 143사)

• Actelion Pharmaceuticals Ltd.
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim GmbH
• Daiichi Sankyo Co., Ltd.
• Johnson & Johnson
• Lupin Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Novartis International AG
• Pfizer, Inc.
• Sanofi
• Takeda Pharmaceutical Co., Ltd.

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향 및 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 스페인
• 러시아
• 기타 유럽
• 아시아태평양
• 호주
• 인도
• 한국
• 기타 아시아태평양
• 라틴아메리카
• 아르헨티나
• 브라질
• 멕시코
• 기타 라틴아메리카
• 중동
• 이란
• 이스라엘
• 사우디아라비아
• 아랍에미리트(UAE)
• 기타 중동
• 아프리카

제4장 경쟁

영문목차

Global Anti-Hypertensive Drugs Market to Reach US$29.7 Billion by 2030

The global market for Anti-Hypertensive Drugs estimated at US$24.6 Billion in the year 2023, is expected to reach US$29.7 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2023-2030. Calcium Channel Blockers, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$7.2 Billion by the end of the analysis period. Growth in the ACE Inhibitors segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.7 Billion While China is Forecast to Grow at 4.7% CAGR

The Anti-Hypertensive Drugs market in the U.S. is estimated at US$6.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.8 Billion by the year 2030 trailing a CAGR of 4.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Anti-Hypertensive Drugs Market - Key Trends and Drivers Summarized

The global market for anti-hypertensive drugs is a major segment within the pharmaceutical industry, driven largely by the widespread prevalence of hypertension, which affects approximately 1.5 billion people worldwide. Despite hypertension being one of the most common chronic diseases globally, there has been a noticeable decline in innovative research on blood pressure mechanisms and new treatments in recent years. This decline is particularly concerning given the rising burden of the disease, especially in low-income countries, coupled with ongoing issues of underdiagnosis and undertreatment in wealthier nations.

The demand for anti-hypertensive medications continues to grow, fueled by an aging population, increasing rates of obesity, sedentary lifestyles, and poor dietary choices such as high salt intake. In response, the market is seeing a shift towards the development of new drug therapies that offer better efficacy, reduced side effects, and improved patient compliance, such as combination therapies that incorporate multiple drugs in a single dosage form to simplify treatment regimens. Furthermore, advancements in genomics and biotechnology are paving the way for more personalized approaches to treatment, allowing for medications to be tailored to the genetic profiles of individual patients, enhancing the effectiveness of hypertension management.

Emerging economies are witnessing significant growth in access to anti-hypertensive treatments, driven by expanding middle classes and better health insurance coverage. This expansion is supported by government and healthcare initiatives aimed at increasing public awareness about the risks of high blood pressure and promoting effective management practices. Additionally, the rise of home health monitoring technologies, such as digital blood pressure monitors linked to smartphone apps, is promoting better patient engagement and adherence to treatment by enabling patients to monitor their condition in real-time. However, the industry also faces challenges such as stringent regulatory environments and pressure to reduce drug prices, which are pushing pharmaceutical companies to innovate in cost-effective drug production and distribution methods.

Select Competitors (Total 143 Featured) -

• Actelion Pharmaceuticals Ltd.
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim GmbH
• Daiichi Sankyo Co., Ltd.
• Johnson & Johnson
• Lupin Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Novartis International AG
• Pfizer, Inc.
• Sanofi
• Takeda Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Anti-Hypertensive Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Hypertension Drives Anti-Hypertensive Drugs Market Growth
  • Technological Advancements in Drug Formulations Propel Market Innovation
  • Rising Adoption of Combination Therapies Expands Addressable Market Opportunity
  • Growth in Geriatric Population Strengthens Business Case for Anti-Hypertensive Drugs
  • Awareness, Early Screening & Focus on Hypertension Management Spur Market Growth
  • Integration of Telemedicine in Hypertension Care, a Key Trend Fueling Growth
  • Expansion of Pharmaceutical Industry in Emerging Markets Accelerates Market Growth
  • Increasing Use of Anti-Hypertensive Drugs in Diabetic Patients Sustains Market Growth
  • Rising Demand for Anti-Hypertensive Drugs in Obese Population. Here is the Story
  • Long-acting Anti-Hypertensive Drugs Grow in Popularity
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Anti-Hypertensive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Diuretics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for ACE Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 12: World 16-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 15: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Beta-Adrenergic Blocker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Beta-Adrenergic Blocker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 18: World 16-Year Perspective for Beta-Adrenergic Blocker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Vasodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Vasodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 21: World 16-Year Perspective for Vasodilators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 22: World Anti-Hypertensive Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 23: USA Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: USA 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 26: Canada Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Canada Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: Canada 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• JAPAN
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 29: Japan Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Japan Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: Japan 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• CHINA
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 32: China Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: China Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: China 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• EUROPE
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 35: Europe Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 36: Europe Historic Review for Anti-Hypertensive Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Europe 16-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 38: Europe Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Europe Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Europe 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• FRANCE
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 41: France Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: France Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: France 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• GERMANY
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 44: Germany Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Germany Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Germany 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 47: Italy Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Italy Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Italy 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 50: UK Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: UK Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: UK 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 53: Spain Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Spain Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Spain 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 56: Russia Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Russia Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Russia 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 59: Rest of Europe Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Rest of Europe Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Rest of Europe 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 63: Asia-Pacific Historic Review for Anti-Hypertensive Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Asia-Pacific 16-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Asia-Pacific Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Asia-Pacific 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 68: Australia Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Australia Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Australia 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• INDIA
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 71: India Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: India Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: India 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 74: South Korea Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: South Korea Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: South Korea 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 77: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Rest of Asia-Pacific Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Rest of Asia-Pacific 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 80: Latin America Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 81: Latin America Historic Review for Anti-Hypertensive Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: Latin America 16-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 83: Latin America Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Latin America Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Latin America 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 86: Argentina Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Argentina Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Argentina 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 89: Brazil Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Brazil Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Brazil 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 92: Mexico Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Mexico Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Mexico 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 95: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of Latin America Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of Latin America 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 98: Middle East Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 99: Middle East Historic Review for Anti-Hypertensive Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Middle East 16-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 101: Middle East Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Middle East Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Middle East 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 104: Iran Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Iran Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Iran 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 107: Israel Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Israel Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Israel 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 110: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Saudi Arabia Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Saudi Arabia 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 113: UAE Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: UAE Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: UAE 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 116: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Rest of Middle East Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: Rest of Middle East 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030
• AFRICA
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 119: Africa Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Africa Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: Africa 16-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2014, 2024 & 2030

IV. COMPETITION